Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects

NCT03375307 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03375307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03375307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 3, 2020
Completion date
December 16, 2026
Enrollment
60 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced bladder carcinoma, advanced genitourinary system carcinoma, metastatic bladder carcinoma, metastatic genitourinary system carcinoma, stage iii bladder cancer ajcc v8, stage iv bladder cancer ajcc v8